Linical Co Piotroski F-Score
The Piotroski F-Score of Linical Co (2183.T) as of Nov 7, 2026 is 3. In the previous year, Piotroski F-Score was 4.00 — a change of -25.00% (lower).
Get this data via API
Financial Data API
Piotroski F-Score
3
YoY
-25.00%
Last updated:
Piotroski F-Score of Linical Co is 2026 3 . Piotroski F-Score of Linical Co was 2025 4.00 . It decreases by -25.00% lower compared to the previous year.
The Linical Co Piotroski F-Score history
3 Years
10 Years
25 Years
Max
Piotroski F-Score
Date
Piotroski F-Score
Jan 1, 2019
2.00 JPY
Jan 1, 2020
5.00 JPY
Jan 1, 2021
5.00 JPY
Jan 1, 2022
8.00 JPY
Jan 1, 2023
7.00 JPY
Jan 1, 2024
5.00 JPY
Jan 1, 2025
4.00 JPY
Jan 1, 2026
3.00 JPY
| YEAR | Piotroski F-Score | YoY |
|---|---|---|
| 3 | -25.00% | |
| 4 | -20.00% | |
| 5 | -28.57% | |
| 7 | -12.50% | |
| 8 | +60.00% | |
| 5 | 0.00% | |
| 5 | +150.00% | |
| 2 | -60.00% | |
| 5 | 0.00% | |
| 5 | -37.50% | |
| 8 | +100.00% | |
| 4 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Linical Co Stock analysis
What does Linical Co do? Linical Co., Ltd. generates revenue through two distinct business segments, the CRO segment and the Pharmaceutical Sales Support segment. The CRO segment provides contract monitoring, quality management, and consulting services specifically for phase II and phase III in drug development processes. These services are delivered to pharmaceutical companies as part of pharmaceutical contract research projects.
The Pharmaceutical Sales Support segment focuses on the downstream market by providing pharmaceutical sales support for medical institutions. The company operates these businesses from its headquarters in Osaka, Osaka-Fu, leveraging its workforce of 759 full-time employees to deliver these specialized services. Linical Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Linical Co stock
Piotroski F-Score of Linical Co is 3 in 2026.
On Eulerpool you can find the complete historical development of Piotroski F-Score Linical Co since 2006 – with annual values, charts, and detailed analysis.
The Piotroski F-Score rates a company from 0-9 based on profitability, leverage, liquidity, and operating efficiency. Scores of 8-9 indicate strong fundamentals.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Linical Co
All Key Metrics — Linical Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth